^
Association details:
| Biomarker: | ARID1A mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
Published date:
09/19/2022
Excerpt:
Patients with ARID1A mutant-like tumors were also less likely to respond (complete or partial confirmed best response) than patients with WT-like tumors when treated with cetuximab, and the proportion of overall confirmed best response rate (ORR) was significantly lower in the ARID1A mutant-like vs. WT-like group....These data are consistent with the concept that the ARID1A mutant-like signature predicts resistance to cetuximab...
DOI:
https://doi.org/10.1038/s41467-022-33172-5
Source:
Title:
Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC
Published date:
05/15/2020
Excerpt:
...our data suggest that ARID1A loss-of-function mutations may promote resistance to cetuximab by driving an EGFR-like transcription program in the absence of ligand-dependent activation of EGFR.
DOI:
10.1158/1538-7445.AM2020-LB-063
